



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
DAHLQVIST et al.

Serial No. 09/937,779

Filed: July 2, 2002

For: NEW CLASS OF ENZYMES IN THE BIOSYNTHETIC PATHWAY FOR THE
PRODUCTION OF TRIACYCLOGLYCEROL AND RECOMBINANT DNA
MOLECULES ENCODING THESE ENZYMES

)
)
) Art Unit: 1652
)
)
)

) Examiner: Kerr, Kathleen
)
)
)

*Fee
purpose
only*

I hereby certify that this correspondence is being to: Commissioner
of Patents and Trademarks, PO Box 1450, Alexandria, VA 22313-
1450, on:

12/15/04

Date of Deposit

Daniel Kim

Person Making Deposit

Dan Ki

Signature

12/15/04

Date of Signature

Honorable Comm'r. of Patents
PO Box 1450
Alexandria, VA 22313-1450

REPLY TO RESTRICTION REQUIREMENT

Sir:

In response the office action dated September 15, 2004, kindly enter the
following amendment and consider the following remarks:

01/18/2005 DILLIA 00000001 110345 0937,779

01 FC:1252 450.00 LA

FEE VALUE ACCOUNTABILITY	
DEPOSIT ACCOUNT NO.	
1110345	
FEE CODE	VALUE FURNISHED
1252	450.00

(2)

REMARKS

Applicants herein elect with traverse Group D (claims 46 and 48).

PCT Rule 13.2 states: Where a group of inventions is claimed in one and the same international application, the requirement of unity of invention referred to in Rule 13.1 shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features.

The elected claims 46 and 48 are directed to the process of producing triacylglycerol. Catalysts occurs with the transfer of fatty acids from phospholipids to diacylglycerol in the production of triacylglycerol through an acyl-CoA independent reaction. Also, the PDAT enzyme of the present invention which is used in the process is characterized through an amino acid conserved consensus sequence as disclosed in the attached table. Therefore, applicants believe all of the claimed sequences should be examined together. Applicants also remind the examiner that the Commissioner has decided *sua sponte* to partially waive the requirements of 37 CFR 1.141 *et seq.* and permit a reasonable number of such nucleotide sequences to be claimed in a single application. MPEP 803.04.

Applicants herein request a two month extension of time.

Please charge any shortage in fees due in connection with the filing of this paper, including Extension of Time fees to Deposit Account No. 11-0345. Please credit any excess fees to such deposit account.

Respectfully submitted,

KEIL & WEINKAUF

A handwritten signature in black ink, appearing to read 'D. Kim', written over the firm name.

Daniel S. Kim

Reg. No. 51877

1350 Connecticut Ave., N.W.
Washington, D.C. 20036
(202)659-0100
DSK